Money will of course be no object when it comes to funding development of treatments for Covid-19, but how much exactly are we talking?
Another trial seems to suggest that adding VEGF blockade to Parp inhibition does little for patients without tumour mutations.
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Glaxosmithkine and Merck & Co succumb to the urge to demerge, joining other big drug makers in pruning their businesses.
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.